Vitrafy Life Sciences Ltd (ASX: VFY) — Company Overview, News & Financial Data
Vitrafy Life Sciences Ltd is a biotechnology company that develops controlled-rate freezing hardware and intelligent cloud software for cryopreservation workflows.
Vitrafy Life Sciences Ltd
Vitrafy Life Sciences Ltd is a biotechnology company that develops controlled-rate freezing hardware and intelligent cloud software for cryopreservation workflows. The company's ecosystem integrates precision-engineered freezing equipment with cloud-based software to preserve biological materials, including human blood platelets, cell and gene therapy T-cells, and animal reproductive materials. Vitrafy serves clinical healthcare, life sciences research, combat casualty care, and aquaculture industries by providing automated, liquid-nitrogen-free cryopreservation technology designed to maintain post-thaw viability and streamline bio-material supply chains across global research and medical facilities.
Snapshot
Operations
Products and/or services of Vitrafy Life Sciences Ltd
- Precision Controlled Freezing Hardware: Custom-engineered hardware delivering rapid, liquid-nitrogen-free cryogenic freezing with high throughput per hour, reaching target cryogenic temperatures under five minutes to preserve cell viability during cryopreservation.
- Intelligent Cryopreservation Software: Cloud-connected workflow management software that monitors, tracks, and logs cryopreservation data in real time, standardizing freezing protocols and ensuring complete chain-of-custody tracking across biological sample lifecycles.
- Blood and Platelet Cryopreservation Solutions: Specialized freezing technology designed for human blood services and combat casualty care, improving post-thaw recovery rates of blood platelets to eliminate wash steps and extend clinical shelf life.
- Cell and Gene Therapy Processing: Advanced cryopreservation workflows for cell therapy developers, ensuring post-thaw viability of fragile T-cells comparable to fresh samples to streamline complex therapy manufacturing and supply chains.
- Animal Reproduction and Aquaculture Applications: Cryogenic preservation solutions tailored for livestock breeding programs and aquaculture operations, enhancing post-thaw sperm quality and fertilization success rates across commercial aquatic and terrestrial animal species.
- Research and Optimization Services: Advisory and testing services for biotechnology laboratories and research institutions, optimizing bio-material freezing protocols and validating cryopreservation workflows to improve post-thaw quality at commercial scale.
Vitrafy Life Sciences Ltd executive team
- Brenton Michael Leslie OwensCo-Founder, MD, CEO & Executive Director
- Simon Thomas MartinChief Financial Officer
- Heather PidcokeChief Science Officer
- Timothy P. CostelloEVP& Chief Commercial Officer
- Michael SapountzisCompany Secretary
Recent announcements
What Vitrafy Life Sciences Ltd (VFY) has told the market, newest first.
- Investor Roadshow Presentation
- Change to CEO Remuneration and Employment Terms
- Vitrafy Share Purchase Plan Opens - SPP Offer BookletPrice sensitive
- Cleansing Notice
- Application for quotation of securities - VFY
Key financials
Reported results for Vitrafy Life Sciences Ltd, in AUD.
- Market cap
- 186.8M
- Revenue (TTM)
- 209K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 168.7K | -20.4M | -16.2M | |
| 65.1K | -16.6M | -32.7M | |
| 37K | -10.7M | -10.4M | |
| 32K | -9.2M | -7.8M |